ESPERANCE PHARMACEUTICALS, INC.

Pioneering a new era of anticancer treatment with drugs that precisely target and eliminate cancer cells while sparing healthy ones.

Founded 2006 11 employees Series B Total: $28.70M Biotechnology, Health Care +1

ESPERANCE PHARMACEUTICALS, INC. is pioneering a new era of anticancer treatment with drugs that precisely target and eliminate cancer cells while sparing healthy ones. Founded in 2006, the company is at the forefront of developing a new generation of anticancer medications that exclusively target and destroy cancer cells, leaving healthy cells unharmed. This revolutionary targeting is achieved by binding to specific receptors on the cell's surface, enabling the drugs to effectively eliminate even those cancer cells that are resistant to traditional chemotherapy treatments. The last investment in ESPERANCE PHARMACEUTICALS, INC. was a notable $7.50M Series B investment on 01 June 2011. The investors in this round included Advantage Capital Partners, Lousiana Funds, Themelios Ventures, Sanofi, and Louisiana Technology Innovation Fund. Esperance Pharmaceuticals operates within the Biotechnology, Health Care, and Pharmaceutical industries, solidifying its position as a key player in the life sciences sector. The company's focus on developing targeted cancer treatments represents a promising advancement in the field, offering potential benefits for both patients and the healthcare industry at large.

Funding Stage	Amount	Investors	Lead Investors	Date
Series B	$7.50M	5	Advantage Capital Partners, Themelios Ventures +3	01 Jun 2011
Venture Round	$9.00M	-		03 May 2010
Series A	$3.20M	3	RCT, Louisiana Funds +1	24 Nov 2008
Series A	$9.00M	2	RCT, Themelios Ventures	31 Oct 2006

Funding Stage

Amount

Investors

Lead Investors

Date

Series B

$7.50M

Advantage Capital Partners, Themelios Ventures +3

01 Jun 2011

Venture Round

$9.00M

03 May 2010

Series A

$3.20M

RCT, Louisiana Funds +1

24 Nov 2008

Series A

$9.00M

RCT, Themelios Ventures

31 Oct 2006

FAQ About ESPERANCE PHARMACEUTICALS, INC.

Pioneering a new era of anticancer treatment with drugs that precisely target and eliminate cancer cells while sparing healthy ones.

ESPERANCE PHARMACEUTICALS, INC. was founded in 2006.

ESPERANCE PHARMACEUTICALS, INC. operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on anticancer treatment, targeted therapy, cancer drug development and precision medicine.

ESPERANCE PHARMACEUTICALS, INC. has approximately 11 employees.

ESPERANCE PHARMACEUTICALS, INC. has completed 4 funding rounds, raising a total of $28.70M. The latest funding stage is Series B.

Top alternatives and competitors to ESPERANCE PHARMACEUTICALS, INC. include ORIC Pharmaceuticals Inc., AtG Therapeutics, ApoGen Biotechnologies, Inc., Endocyte, Orum Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

ESPERANCE PHARMACEUTICALS, INC. and ORIC Pharmaceuticals Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

ESPERANCE PHARMACEUTICALS, INC.

General Information

Discover More

About ESPERANCE PHARMACEUTICALS, INC.

Funding Rounds & Investors (4)

ESPERANCE PHARMACEUTICALS, INC. Alternatives & Competitors

FAQ About ESPERANCE PHARMACEUTICALS, INC.